RU2105773C1 - Способ получения стабильных в кислой среде производных бензимидазола - Google Patents

Способ получения стабильных в кислой среде производных бензимидазола Download PDF

Info

Publication number
RU2105773C1
RU2105773C1 RU94031478A RU94031478A RU2105773C1 RU 2105773 C1 RU2105773 C1 RU 2105773C1 RU 94031478 A RU94031478 A RU 94031478A RU 94031478 A RU94031478 A RU 94031478A RU 2105773 C1 RU2105773 C1 RU 2105773C1
Authority
RU
Russia
Prior art keywords
group
cyclodextrin
solution
buffer
omeprazole
Prior art date
Application number
RU94031478A
Other languages
English (en)
Russian (ru)
Other versions
RU94031478A (ru
Inventor
Сан Мин Донг
Ан Ум Ки
Соо Ким Йонг
Ук Парк Пьеонг
Original Assignee
Санкионг Индастриз Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санкионг Индастриз Ко., Лтд. filed Critical Санкионг Индастриз Ко., Лтд.
Publication of RU94031478A publication Critical patent/RU94031478A/ru
Application granted granted Critical
Publication of RU2105773C1 publication Critical patent/RU2105773C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU94031478A 1991-12-31 1992-12-30 Способ получения стабильных в кислой среде производных бензимидазола RU2105773C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR91-25847 1991-12-31
KR910025847 1991-12-31
PCT/KR1992/000083 WO1993013138A1 (en) 1991-12-31 1992-12-30 A method for preparing enteric-coated oral drugs containing acid-unstable compounds

Publications (2)

Publication Number Publication Date
RU94031478A RU94031478A (ru) 1996-01-20
RU2105773C1 true RU2105773C1 (ru) 1998-02-27

Family

ID=19327322

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94031478A RU2105773C1 (ru) 1991-12-31 1992-12-30 Способ получения стабильных в кислой среде производных бензимидазола

Country Status (15)

Country Link
US (1) US5399700A (enExample)
EP (1) EP0619825B1 (enExample)
JP (1) JP2662518B2 (enExample)
KR (1) KR960008231B1 (enExample)
CN (1) CN1033790C (enExample)
BR (1) BR9207000A (enExample)
CA (1) CA2127111C (enExample)
DE (1) DE69222950T2 (enExample)
EG (1) EG20115A (enExample)
ES (1) ES2111148T3 (enExample)
HU (1) HU217135B (enExample)
MX (1) MX9207676A (enExample)
RU (1) RU2105773C1 (enExample)
TW (1) TW224049B (enExample)
WO (1) WO1993013138A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2279276C2 (ru) * 2000-01-11 2006-07-10 Зе Курэйторз Оф Зе Юниверсити Оф Миссури Новые лекарственные формы замещенных бензимидазолов и способы их применения
RU2313343C2 (ru) * 2001-06-06 2007-12-27 Сипла Лимитед Комплекс включения s-омепразола (эсомепразола) с циклодекстрином

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5780696A (en) * 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole
RU2161481C2 (ru) * 1995-09-21 2001-01-10 Фарма Пасс Ллс Новая композиция, содержащая кислотно-нестойкий омепразол, и способ ее получения
ES2236628T3 (es) * 1995-09-21 2005-07-16 Pharma Pass Ii Llc Composicion farmaceutica que contiene un omeprazol labil de acido, y procedimiento para su preparacion.
AU745707B2 (en) * 1995-09-21 2002-03-28 Pharma Pass Llc novel composition containing an acid-labile omeprazole and process for its preparation
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
IL131651A0 (en) * 1997-03-13 2001-01-28 Hexal Ag A pharmaceutical formulation containing benzimidazoles with amino acid/caclodextrin combinations and a process for producing the same
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
KR100281521B1 (ko) * 1998-03-31 2001-02-15 김종인 프라바스타틴나트륨이 함유된 약제 조성물
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
BR9916361A (pt) * 1998-12-18 2002-11-05 Abbott Lab Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
US20050171057A1 (en) * 2002-01-15 2005-08-04 Altana Pharma Ag Pantoprazole cyclodextrin inclusion complexes
MXPA04007169A (es) * 2002-01-25 2004-10-29 Santarus Inc Suministro transmucosal de inhibidores de bomba de protones.
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
US20070060556A1 (en) * 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
KR100473422B1 (ko) * 2003-06-12 2005-03-14 박원봉 렉틴 함유 천연물의 장용성 코팅용 조성물
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MXPA06000524A (es) * 2003-07-18 2006-08-11 Santarus Inc Formulacion farmaceutica y metodo para tratar desordenes gastrointestinales provocados por acido.
TWI398273B (zh) * 2003-07-18 2013-06-11 Santarus Inc 用於抑制酸分泌之醫藥調配物及其製備及使用之方法
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
KR20050105565A (ko) * 2004-04-30 2005-11-04 에스케이케미칼주식회사 저장안정성이 우수한 벤즈이미다졸 유도체 함유 포접복합체 및 이의 제조방법
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006085335A2 (en) * 2005-01-03 2006-08-17 Lupin Limited Pharmaceutical composition of acid labile substances
CA2654402A1 (en) * 2006-06-01 2007-12-06 Adel Penhasi Multiple unit pharmaceutical formulation
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
ITMI20121264A1 (it) * 2012-07-19 2014-01-20 Recordati Ind Chimica E Farma Ceutica S P A Forma farmaceutica gastro-resistente a rilascio ritardato
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1433823A (en) * 1972-06-19 1976-04-28 Goetaverken Angteknik Ab Furnace wall containing spaced parallel water tubes and blocks mounted thereon
GB2239020B (en) * 1989-10-24 1993-07-21 Kalamazoo Holdings Inc Norbixin adducts with water-soluble or water-dispersible proteins or branched-chain or cyclic polysaccharides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2260536C3 (de) * 1972-12-11 1975-07-10 Fa. H. Trommsdorff, 5100 Aachen MolekiileinschluBverbindungen aus einem Silberalkanolammin-Komplex und beta-Cycloheptaamylose, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3427787A1 (de) * 1984-07-27 1986-01-30 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1433823A (en) * 1972-06-19 1976-04-28 Goetaverken Angteknik Ab Furnace wall containing spaced parallel water tubes and blocks mounted thereon
GB2239020B (en) * 1989-10-24 1993-07-21 Kalamazoo Holdings Inc Norbixin adducts with water-soluble or water-dispersible proteins or branched-chain or cyclic polysaccharides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
РСТ, заявка, 86100913, кл. C 08 B 37/16, 1986. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2279276C2 (ru) * 2000-01-11 2006-07-10 Зе Курэйторз Оф Зе Юниверсити Оф Миссури Новые лекарственные формы замещенных бензимидазолов и способы их применения
RU2313343C2 (ru) * 2001-06-06 2007-12-27 Сипла Лимитед Комплекс включения s-омепразола (эсомепразола) с циклодекстрином

Also Published As

Publication number Publication date
ES2111148T3 (es) 1998-03-01
HU9401666D0 (en) 1994-09-28
HUT70494A (en) 1995-10-30
MX9207676A (es) 1993-06-01
EG20115A (en) 1997-07-31
US5399700A (en) 1995-03-21
KR930012016A (ko) 1993-07-20
DE69222950T2 (de) 1998-05-28
CN1033790C (zh) 1997-01-15
JP2662518B2 (ja) 1997-10-15
BR9207000A (pt) 1995-11-28
KR960008231B1 (ko) 1996-06-21
EP0619825B1 (en) 1997-10-29
DE69222950D1 (de) 1997-12-04
EP0619825A1 (en) 1994-10-19
TW224049B (enExample) 1994-05-21
CA2127111A1 (en) 1993-07-08
CN1076124A (zh) 1993-09-15
JPH07506088A (ja) 1995-07-06
WO1993013138A1 (en) 1993-07-08
CA2127111C (en) 1996-05-21
HU217135B (hu) 1999-11-29

Similar Documents

Publication Publication Date Title
RU2105773C1 (ru) Способ получения стабильных в кислой среде производных бензимидазола
KR100350138B1 (ko) 산-분해성오메프라졸을함유하는신규조성물과그의제조과정
JP3536106B2 (ja) 製剤及びその製造方法
KR19990008249A (ko) 경구 투여용 조성물
CN1146558C (zh) 新的邦托拉唑盐
HUT64961A (en) Inclusion complexes of clavulanic acid with hydrophylic and hydrophobic beta-cyclodextrin derivatives and method for producint them
JPH05294831A (ja) 内服用新規医薬製剤
HU198385B (en) Process for producing peroral pharmaceutical compositions containing acid-sensitive benzimidazol derivatives for treating gastrointestinal illnesses
EP1018340B1 (en) Inclusion aminoacid salts compounds of benzimidazole derivatives with cyclodextrins, their preparation and pharmaceutical formulations containing them
EP1855690B1 (en) A tetracycline metal complex in a solid dosage form
RU2228331C2 (ru) Нитратные соли гетероциклических соединений, способ их получения и фармацевтические композиции на их основе
JPH08511009A (ja) ジクロフェナックを含有する経口固体剤形の製造方法
BG99021A (bg) Фармацевтични състави,съдържащи производни на фурана
HUP0600143A2 (en) A stable pharmaceutical formulation comprising torsemide modification ii
WO1989006959A1 (fr) Preparation pharmaceutique a liberation amelioree
US20070212408A1 (en) Stable Pharmaceutical Composition Containing Benzimidazole Derivatives and Method of Manufacturing the Same
RU2108109C1 (ru) Способ получения комплекса силибинина с циклодекстрином, комплекс включения силибинина с циклодекстрином, фармацевтическая композиция антигепатотоксической активности и способ ее получения
US20250009670A1 (en) Stable Solid Oral Formulation Of Tafamidis Or Pharmaceutically Acceptable Salt Thereof
JP2007513146A (ja) 液体系プロセスによるアジスロマイシンマルチパーティキュレート剤形
JPH01287094A (ja) ダナゾール−シクロデキストリン包接化合物
WO2025166343A1 (en) Tablet formulation of tafamidis or pharmaceutically acceptable salt thereof
EP0535269A1 (en) Pharmaceutical compositions containing thiazolidinedione derivatives
US20250248977A1 (en) Tablet Formulation Of Tafamidis Or Pharmaceutically Acceptable Salt Thereof
KR960015143B1 (ko) 벤즈이미다졸유도체를 함유하는 신규 경구형 제제 및 그 제조방법
MXPA97002824A (en) ou. PHARMACEUTICAL PREPARATIONS OF DERIVATIVES OF MACROLIDICOS DE SEGUNDA GENERAC ANTIBIOTICS